The optimal interval before receiving SARS-COV-2 vaccination for patients who have received Anti-CD 20 monoclonal antibodies
The optimal interval before receiving SARS-COV-2 vaccination for patients who have received anti-CD 20 monoclonal antibodies remains unclear. We considered original studies up to 29 October 2022 and conducted searches in Embase,Medrxiv, PubMed, and SSRN. We excluded search results that did not match...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2022-12-01
|
| Series: | Virulence |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/21505594.2022.2146380 |
| _version_ | 1828128532010631168 |
|---|---|
| author | Kexin Liu Jinyu Li Gaosi Xu |
| author_facet | Kexin Liu Jinyu Li Gaosi Xu |
| author_sort | Kexin Liu |
| collection | DOAJ |
| description | The optimal interval before receiving SARS-COV-2 vaccination for patients who have received anti-CD 20 monoclonal antibodies remains unclear. We considered original studies up to 29 October 2022 and conducted searches in Embase,Medrxiv, PubMed, and SSRN. We excluded search results that did not match our research question’s subject. Human immune response outcomes were analysed inpatients who had previously received anti-CD20 antibody therapy. We analyzed the collected results using sensitivity curves and forest plots. Twenty-eight studies with a total of 1455 subjects receiving anti-CD20 monoclonal antibodies were included in the present analysis. The humoral immune response rates to the time between the last anti-CD20 treatment and vaccination for 3–6 months, 6 months,6–9 months, and 9–12 months were 0.23 (95% CI 0.14 to 0.36), 0.36 (95% CI 0.19 to 0.58), 0.49 (95% CI 0.35 to 0.64) and 0.64 (95% CI 0.48 to 0.77),respectively. The humoral immune response rates were.16 (95% CI 0.03 to 0.57) when B cell was 0/ul, and 0.49 (95% CI 0.38 to 0.61)when B cells were more than 5/ul. The humoral immune response rate for multiple sclerosis was 0.39 (95% CI 0.22 to 0.60) and 0.48 (95% CI 0.29 to 0.68) for B-cell non-Hodgkin lymphoma. The area underneath the curve(AUC) was 0.69 with a cut-off value of 5.5 months. The present results suggested that the optimal interval for SARS-COV-2 vaccination after the final dose of anti-CD20 monoclonal antibody was 5.5 months. |
| first_indexed | 2024-04-11T16:06:18Z |
| format | Article |
| id | doaj.art-8a2040db82b94891be3e3fb32d1f47ed |
| institution | Directory Open Access Journal |
| issn | 2150-5594 2150-5608 |
| language | English |
| last_indexed | 2024-04-11T16:06:18Z |
| publishDate | 2022-12-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Virulence |
| spelling | doaj.art-8a2040db82b94891be3e3fb32d1f47ed2022-12-22T04:14:49ZengTaylor & Francis GroupVirulence2150-55942150-56082022-12-011312012202110.1080/21505594.2022.2146380The optimal interval before receiving SARS-COV-2 vaccination for patients who have received Anti-CD 20 monoclonal antibodiesKexin Liu0Jinyu Li1Gaosi Xu2Department of Nephrology, The Second Affiliated Hospital of Nanchang University, Nanchang, ChinaGrade 2020, The First Clinical Medical College of Nanchang University, Nanchang, Jiangxi, ChinaDepartment of Nephrology, The Second Affiliated Hospital of Nanchang University, Nanchang, ChinaThe optimal interval before receiving SARS-COV-2 vaccination for patients who have received anti-CD 20 monoclonal antibodies remains unclear. We considered original studies up to 29 October 2022 and conducted searches in Embase,Medrxiv, PubMed, and SSRN. We excluded search results that did not match our research question’s subject. Human immune response outcomes were analysed inpatients who had previously received anti-CD20 antibody therapy. We analyzed the collected results using sensitivity curves and forest plots. Twenty-eight studies with a total of 1455 subjects receiving anti-CD20 monoclonal antibodies were included in the present analysis. The humoral immune response rates to the time between the last anti-CD20 treatment and vaccination for 3–6 months, 6 months,6–9 months, and 9–12 months were 0.23 (95% CI 0.14 to 0.36), 0.36 (95% CI 0.19 to 0.58), 0.49 (95% CI 0.35 to 0.64) and 0.64 (95% CI 0.48 to 0.77),respectively. The humoral immune response rates were.16 (95% CI 0.03 to 0.57) when B cell was 0/ul, and 0.49 (95% CI 0.38 to 0.61)when B cells were more than 5/ul. The humoral immune response rate for multiple sclerosis was 0.39 (95% CI 0.22 to 0.60) and 0.48 (95% CI 0.29 to 0.68) for B-cell non-Hodgkin lymphoma. The area underneath the curve(AUC) was 0.69 with a cut-off value of 5.5 months. The present results suggested that the optimal interval for SARS-COV-2 vaccination after the final dose of anti-CD20 monoclonal antibody was 5.5 months.https://www.tandfonline.com/doi/10.1080/21505594.2022.2146380Anti-cd20vaccinerituximabSars-CoV-2COVID-19 |
| spellingShingle | Kexin Liu Jinyu Li Gaosi Xu The optimal interval before receiving SARS-COV-2 vaccination for patients who have received Anti-CD 20 monoclonal antibodies Virulence Anti-cd20 vaccine rituximab Sars-CoV-2 COVID-19 |
| title | The optimal interval before receiving SARS-COV-2 vaccination for patients who have received Anti-CD 20 monoclonal antibodies |
| title_full | The optimal interval before receiving SARS-COV-2 vaccination for patients who have received Anti-CD 20 monoclonal antibodies |
| title_fullStr | The optimal interval before receiving SARS-COV-2 vaccination for patients who have received Anti-CD 20 monoclonal antibodies |
| title_full_unstemmed | The optimal interval before receiving SARS-COV-2 vaccination for patients who have received Anti-CD 20 monoclonal antibodies |
| title_short | The optimal interval before receiving SARS-COV-2 vaccination for patients who have received Anti-CD 20 monoclonal antibodies |
| title_sort | optimal interval before receiving sars cov 2 vaccination for patients who have received anti cd 20 monoclonal antibodies |
| topic | Anti-cd20 vaccine rituximab Sars-CoV-2 COVID-19 |
| url | https://www.tandfonline.com/doi/10.1080/21505594.2022.2146380 |
| work_keys_str_mv | AT kexinliu theoptimalintervalbeforereceivingsarscov2vaccinationforpatientswhohavereceivedanticd20monoclonalantibodies AT jinyuli theoptimalintervalbeforereceivingsarscov2vaccinationforpatientswhohavereceivedanticd20monoclonalantibodies AT gaosixu theoptimalintervalbeforereceivingsarscov2vaccinationforpatientswhohavereceivedanticd20monoclonalantibodies AT kexinliu optimalintervalbeforereceivingsarscov2vaccinationforpatientswhohavereceivedanticd20monoclonalantibodies AT jinyuli optimalintervalbeforereceivingsarscov2vaccinationforpatientswhohavereceivedanticd20monoclonalantibodies AT gaosixu optimalintervalbeforereceivingsarscov2vaccinationforpatientswhohavereceivedanticd20monoclonalantibodies |